Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INCY

Incyte Corp.

Jul 26 • 04:00PM ET

68.61

Dollar change +0.04
Percentage change 0.06	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO VO XBI COWZ USMV VUG SPY RSP IVV

Scroll to Statements

Index	S&P 500	P/E	20.82	EPS (ttm)	3.29	Insider Own	1.63%	Shs Outstand	224.29M	Perf Week	4.16%
Market Cap	15.43B	Forward P/E	13.22	EPS next Y	5.19	Insider Trans	-0.80%	Shs Float	221.19M	Perf Month	11.11%
Income	745.44M	PEG	0.90	EPS next Q	0.86	Inst Own	95.46%	Short Float	5.79%	Perf Quarter	34.06%
Sales	3.77B	P/S	4.09	EPS this Y	16.52%	Inst Trans	0.60%	Short Ratio	3.54	Perf Half Y	12.62%
Book/sh	24.02	P/B	2.86	EPS next Y	26.30%	ROA	11.53%	Short Interest	12.81M	Perf Year	9.25%
Cash/sh	17.13	P/C	4.01	EPS next 5Y	23.13%	ROE	15.13%	52W Range	50.27 - 70.36	Perf YTD	9.27%
Dividend Est.	-	P/FCF	19.51	EPS past 5Y	38.99%	ROI	13.75%	52W High	-2.49%	Beta	0.71
Dividend TTM	-	Quick Ratio	3.43	Sales past 5Y	14.55%	Gross Margin	91.46%	52W Low	36.48%	ATR (14)	1.68
Dividend Ex-Date	-	Current Ratio	3.47	EPS Y/Y TTM	127.87%	Oper. Margin	18.91%	RSI (14)	74.84	Volatility	2.96% 2.66%
Employees	2524	Debt/Eq	0.01	Sales Y/Y TTM	8.58%	Profit Margin	19.78%	Recom	2.07	Target Price	71.49
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	675.68%	Payout	0.00%	Rel Volume	0.60	Prev Close	68.57
Sales Surprise	-4.45%	EPS Surprise	-19.46%	Sales Q/Q	8.93%	Earnings	Jul 30 BMO	Avg Volume	3.62M	Price	68.61
SMA20	9.46%	SMA50	13.05%	SMA200	17.95%	Trades		Volume	2,186,042	Change	0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-02-24	Downgrade	BMO Capital Markets	Market Perform → Underperform	$52 → $48
May-23-24	Initiated	Deutsche Bank	Hold	$55
Apr-23-24	Initiated	Cantor Fitzgerald	Neutral
Feb-23-24	Initiated	Jefferies	Buy	$81
Feb-14-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-13-23	Upgrade	Leerink Partners	Market Perform → Outperform	$78
Dec-04-23	Upgrade	Guggenheim	Neutral → Buy	$86
Nov-21-23	Downgrade	Goldman	Buy → Neutral	$98 → $65
Jul-25-23	Initiated	Citigroup	Buy	$82
May-04-23	Downgrade	BofA Securities	Buy → Neutral	$84
Apr-10-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$81 → $79
Mar-24-23	Upgrade	SVB Securities	Underperform → Market Perform	$61
Jan-31-23	Initiated	Piper Sandler	Overweight	$100
Aug-03-22	Downgrade	Guggenheim	Buy → Neutral
Aug-03-22	Downgrade	Evercore ISI	Outperform → In-line	$90 → $78
Jul-28-22	Initiated	Wells Fargo	Equal Weight	$76
Feb-09-22	Downgrade	SVB Leerink	Mkt Perform → Underperform	$60 → $56
Jan-18-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$78 → $90
Nov-19-21	Initiated	BMO Capital Markets	Market Perform	$75
Jul-20-21	Upgrade	The Benchmark Company	Hold → Buy	$89

Show Previous Ratings

Jul-24-24 10:26AM	Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings? (Zacks)
Jul-23-24 10:01AM	Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-15-24 07:00PM	Analyst Report: Incyte Corporation (Morningstar Research)
02:01PM	Incyte (INCY) Gains 19.6% in Three Months: Here's Why (Zacks)
Jul-09-24 05:08PM	S&P 500 Gains and Losses Today: Albemarle Stock Pressured by Weak Lithium Prices (Investopedia)
08:00AM	Loading…
08:00AM	Incyte to Report Second Quarter Financial Results (Business Wire)
06:53AM	The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024 (InvestorPlace)
06:00AM	7 Cheap Biotech Stocks With Major Upside Potential (InvestorPlace)
Jul-08-24 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-05-24 06:20AM	3 Highly Rated Biotech Stocks for Your July Buy List (InvestorPlace)
Jul-02-24 05:27PM	S&P 500 Gains and Losses Today: Index Tops 5,500 as Powell Touts Inflation Progress (Investopedia)
Jul-01-24 02:18PM	7 Undervalued Biotech Stocks to Buy for Big-Time Returns (InvestorPlace)
Jun-14-24 03:00PM	Insider Sale: EVP & General Manager US Barry Flannelly Sells 19,164 Shares of Incyte Corp (INCY) (GuruFocus.com)
Jun-13-24 08:00AM	Incyte Announces Final Results of Tender Offer (Business Wire)
Jun-11-24 08:00AM	Incyte Announces Preliminary Results of Tender Offer (Business Wire)
04:30PM	Loading…
Jun-07-24 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-30-24 04:05PM	Incyte Completes Acquisition of Escient Pharmaceuticals (Business Wire)
11:31AM	Incyte (INCY) Up 7.5% Since Last Earnings Report: Can It Continue? (Zacks)
May-21-24 01:15PM	Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings (Business Wire)
08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
May-17-24 12:24PM	Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week (Zacks)
May-14-24 05:00PM	Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress (Business Wire)
03:18AM	Heard on the Street Monday Recap: Hello Kitty (The Wall Street Journal)
May-13-24 05:24PM	Health Care Roundup: Market Talk (The Wall Street Journal) +8.56%
05:23PM	S&P 500 Gains and Losses Today: Incyte Stock Pops on Buyback Plan (Investopedia)
01:49PM	Sector Update: Health Care Stocks Mixed in Afternoon Trading (MT Newswires)
12:41PM	Incyte, Squarespace rise; Chimera Investment, Amazon fall, Monday, 5/13/2024 (Associated Press Finance)
10:57AM	Incyte Stock Marks Biggest Jump in 7 Years on Dutch Auction Buyback Plan. How It Works. (Barrons.com)
09:24AM	Sector Update: Health Care Stocks Decline Pre-Bell Monday (MT Newswires)
09:14AM	Incyte Stock Jumps on Dutch Auction Buyback Plan. How It Works. (Barrons.com)
08:24AM	Loading…
08:24AM	Incyte Launches $1.67 Billion Share Repurchase 'Dutch Auction' Tender Offer; to Buy Back $328 Million of Baker Entities' Shares (MT Newswires)
07:00AM	Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock (Business Wire)
May-12-24 08:26AM	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 03:17PM	MacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 06:15AM	The 3 Best Biotech Stocks to Buy in May 2024 (InvestorPlace)
May-02-24 11:17PM	Q1 2024 Insight Enterprises Inc Earnings Call (Thomson Reuters StreetEvents)
08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
May-01-24 11:24AM	TD Cowen Adjusts Price Target on Incyte to $80 From $88 (MT Newswires)
11:12AM	Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:53AM	RBC Capital Adjusts Price Target on Incyte to $60 From $65 (MT Newswires)
10:33AM	Piper Sandler Adjusts Price Target on Incyte to $80 From $85 (MT Newswires)
10:20AM	Goldman Sachs Adjusts Price Target on Incyte to $60 From $63 (MT Newswires)
08:55AM	Leerink Partners Adjusts Price Target on Incyte to $80 From $83, Keeps Outperform Rating (MT Newswires)
07:58AM	Citigroup Adjusts Price Target on Incyte to $80 From $81 (MT Newswires)
07:50AM	BMO Capital Adjusts Incyte Price Target to $52 From $56 (MT Newswires)
Apr-30-24 04:31PM	Analyst Report: Incyte Corporation (Morningstar Research)
02:57PM	Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained (MT Newswires)
11:54AM	INCY Stock Earnings: Incyte Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
11:50AM	Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
10:10AM	Incyte misses quarterly profit on weak sales of lead drug (Reuters)
09:36AM	Incyte's Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed (MT Newswires)
09:30AM	Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:34AM	Incyte Corp (INCY) Q1 2024 Earnings: Misses Revenue Estimates but Shows Strong Growth in ... (GuruFocus.com)
07:10AM	Incyte: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs (Business Wire)
Apr-23-24 10:12AM	Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M (FierceBiotech.com)
10:01AM	Incyte (INCY) Earnings Expected to Grow: Should You Buy? (Zacks)
09:44AM	Incyte (INCY) to Report Q1 Earnings: What's in the Cards? (Zacks)
07:00AM	Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists (Business Wire)
Apr-15-24 05:30AM	Certain Biotech Investors Get an Early Look at Results. Is That Fair? (The Wall Street Journal)
Apr-11-24 08:00AM	Incyte to Report First Quarter Financial Results (Business Wire)
Apr-06-24 08:56AM	Biotech Executive Who Bet on Rivals Stock Committed Insider Trading, Jury Says (The Wall Street Journal)
Apr-01-24 08:30AM	Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia (Business Wire)
08:30AM	CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia (GlobeNewswire)
Mar-31-24 11:53AM	12 Best S&P 500 Stocks To Buy According to Analysts (Insider Monkey)
Mar-29-24 04:30PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-24 02:47PM	SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive (Bloomberg)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-15-24 10:37AM	MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 11:30AM	Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report? (Zacks)
08:18AM	MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-12-24 01:52PM	Incyte (INCY) Posts Positive Results on Opzelura From HS Study (Zacks)
Mar-11-24 01:02PM	Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead (InvestorPlace)
07:18AM	Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial (FierceBiotech.com)
Mar-10-24 04:05PM	Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis (Business Wire)
04:05PM	Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura) in Patients with Mild-to-Moderate Hidradenitis Suppurativa (Business Wire)
Mar-07-24 03:00PM	3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise (InvestorPlace)
Mar-04-24 08:00AM	New Data from Incytes Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Mar-03-24 08:29AM	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 10:19AM	Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients Lives through Generative AI (Business Wire)
07:30AM	Knight Therapeutics Announces Launch of Minjuvi in Brazil (GlobeNewswire)
Feb-28-24 01:10PM	Q4 2023 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 04:08PM	Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease (Business Wire)
Feb-26-24 03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace)
Feb-21-24 04:50PM	Exit Now! 3 Biotech Stocks to Sell in February 2024 (InvestorPlace)
Feb-15-24 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
Feb-14-24 09:32AM	Incyte Corporation (NASDAQ:INCY) Q4 2023 Earnings Call Transcript (Insider Monkey)
01:15AM	Q4 2023 Incyte Corp Earnings Call (Thomson Reuters StreetEvents)
12:12AM	Decoding Incyte Corp (INCY): A Strategic SWOT Insight (GuruFocus.com)
Feb-13-24 05:43PM	Analyst Report: Incyte Corporation (Morningstar Research)
11:37AM	Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates (Zacks)
09:30AM	Here's What Key Metrics Tell Us About Incyte (INCY) Q4 Earnings (Zacks)
08:26AM	Incyte misses quarterly profit estimates due to higher costs (Reuters)
08:25AM	Incyte (INCY) Lags Q4 Earnings and Revenue Estimates (Zacks)
07:38AM	Incyte Corp (INCY) Reports Solid Growth in 2023, Sets Sights on Future Pipeline Expansion (GuruFocus.com)
07:35AM	Incyte Q4 Adj EPS Misses Estimates, But Revenues Top (RTT News)
07:34AM	Incyte: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities (Business Wire)
Feb-09-24 11:03AM	Incyte (INCY) to Report Q4 Earnings: What's in the Cards? (Zacks)
09:15AM	Ahead of Incyte (INCY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flannelly Barry P	EVP & General Manager US	Jul 16 '24	Sale	64.19	1,306	83,832	58,042	Jul 17 12:24 PM
Flannelly Barry P	EVP & General Manager US	Jul 09 '24	Sale	60.00	8,148	488,880	50,534	Jul 11 12:35 PM
Flannelly Barry P	EVP & General Manager US	Jun 12 '24	Sale	60.00	19,164	1,149,840	66,377	Jun 14 12:17 PM
Tray Thomas	Principal Accounting Officer	Jun 06 '24	Sale	58.91	1,093	64,389	21,634	Jun 10 12:25 PM
BAKER BROS. ADVISORS LP	Director	May 07 '24	Option Exercise	49.01	30,000	1,470,300	33,462,981	May 09 06:25 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 03 '24	Sale	65.51	7,365	482,481	90,218	Jan 05 12:27 PM
Iyengar Vijay K	EVP, GMAPPS	Jan 02 '24	Sale	65.00	657	42,705	43,412	Jan 04 01:05 PM
Tray Thomas	Principal Accounting Officer	Dec 13 '23	Sale	62.37	1,067	66,549	23,436	Dec 14 02:11 PM
Tray Thomas	Principal Accounting Officer	Dec 12 '23	Sale	57.36	210	12,046	24,503	Dec 14 02:11 PM
SWAIN PAULA J	EVP, Human Resources	Sep 01 '23	Sale	65.13	8,449	550,283	77,530	Sep 06 04:00 PM
Stein Steven H	EVP & Chief Medical Officer	Aug 01 '23	Sale	63.28	21,511	1,361,216	97,583	Aug 03 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INCY

Incyte Corp.

Upgrade your FINVIZ experience